Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genelabs Technologies has entered into a collaborative research agreement with the National Health Research Institutes, a non-profit foundation established by the government of the Republic of China, and Genovate Biotechnology, a fully integrated biopharmaceutical company in Taiwan.
Subscribe to our email newsletter
The intent of the collaboration between the three parties is to jointly conduct further research to discover and develop compounds that target the hepatitis C virus (HCV).
The National Health Research Institutes (NHRI) and Genelabs scientists will jointly work to discover and develop new HCV drug candidates by utilizing Genelabs’ know-how and lead compounds on an existing target and NHRI’s chemistry and drug discovery expertise.
Ronald Griffith, Genelabs’ CSO, said: “The collaboration will increase the level of chemistry and biology research activities on a selected Genelabs project targeting the HCV virus.”